Effectiveness and Safety of Elagolix Treatment in Moderate to Severe Endometriosis-associated Pain in Routine Clinical Practice in Israel- ENDORSE Study
Latest Information Update: 10 Jun 2024
At a glance
- Drugs Elagolix (Primary)
- Indications Dysmenorrhoea; Endometriosis
- Focus Therapeutic Use
- Acronyms ENDORSE
- Sponsors AbbVie
- 06 Jun 2024 Status changed from active, no longer recruiting to completed.
- 07 Dec 2022 Status changed from recruiting to active, no longer recruiting.
- 18 Jan 2022 Planned End Date changed from 15 Nov 2023 to 30 Apr 2024.